Phase 4
Completed N=30
Continuous Double Ovarian Stimulation.
Fertility Issues
Source: ClinicalTrials.gov NCT05815719 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
May 2025
Primary outcomePrimary: Total Number of Retrieved Oocytes — 13.33; 11.87 oocytes
◆ Published Evidence
Highly cited
357citations · ~16 / year
Characterization of ovarian follicular wave dynamics in women.
Summary
To evaluate the efficacy of the weekly use of corifollitropin alfa in double ovarian stimulation process and to compare it to the conventional protocol with daily medication administration.
Linked Publications (5)
-
Characterization of ovarian follicular wave dynamics in women.
-
Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol).
-
Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles.
-
A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.
-
DuoStim - a reproducible strategy to obtain more oocytes and competent embryos in a short time-frame aimed at fertility preservation and IVF purposes. A systematic review.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Number of Retrieved Oocytes |
13.33; 11.87 | — |
| PRIMARY Number of MII Oocytes |
10.4; 9.2 | — |
| SECONDARY Duration of Ovarian Stimulation |
24.4; 25.2 | — |
| SECONDARY Number of Injections |
4.5; 35.2 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with indication for DUOSTIM protocol
- Maximum age of 43 years (up to one day before their 44th birthday) at the beginning of the stimulation process.
- Ability to participate and comply with the study protocol.
- To have given written consent
Exclusion Criteria
- Finding of ovarian pathology at the time of initiation of stimulation: e.g. ovarian cysts.
- Concurrent participation in another study.
Data sourced from ClinicalTrials.gov (NCT05815719) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.